The Mortar & Pestle Podcast By PCCA - The Leader in Compounding Pharmacy cover art

The Mortar & Pestle

The Mortar & Pestle

By: PCCA - The Leader in Compounding Pharmacy
Listen for free

A podcast for pharmacy focusing on compounding personalized medicine, nutrition, marketing your business, and all things pharmacy..Copyright 2022 All rights reserved. Chemistry Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • HRT Game-Changer for Women's Health with Sara Hover

    HRT Game-Changer for Women's Health with Sara Hover
    Feb 13 2026
    FDA Removes Black Box Warning on Estrogen: HRT Game-Changer for Women's Health After 23 years, the FDA removed the black box warning on estrogen products—a landmark decision transforming hormone replacement therapy (HRT) for women. In this episode of the Mortar and Pestle podcast, hosts Mike De Lisio and Sebastian Dennison discuss this breakthrough with Sara Hover, Senior Director of Clinical Services at PCCA. What You'll Learn:
    • Why the 2002 Women's Health Initiative study was flawed and created decades of HRT concerns
    • The timing hypothesis: why age matters when starting hormone replacement therapy
    • Synthetic vs. bioidentical hormones and their clinical differences
    • Oral estrogen delivery systems and safety implications
    • Shared decision-making between patients, prescribers, and pharmacists
    • Why compounded HRT solutions matter for patients who don't fit commercial products
    • Hormone testing modalities and why multiple testing methods are essential
    • Vaginal estrogen's role in preventing UTIs and hip fractures
    • How pharmacists can educate providers and patients on HRT safety
    Topics Covered: Black box warning removal, hormone replacement therapy, bioidentical hormones, menopause management, compounding pharmacy, women's health, estrogen, patient monitoring, HRT dosing strategies Perfect for: Compounding pharmacists, healthcare providers, and anyone seeking evidence-based information on hormone replacement therapy. Links: The FDA Removes the Black Box Warning on Estrogen: What Pharmacists Need to Know (2025 Update) Why VersaBase Cream Is Your Best Choice for Women's HRT The Vaginal Microbiome, Menopause & HRT A Personalized Approach to HRT for Perimenopausal Women Backed by Science: Anhydrous VersaBase® HRT Optimizing the Patient Experience with the Right HRT Base: Insights from the Webinar
    Show more Show less
    28 mins
  • Methylene Blue Topical Formulations and Advanced Dermatology Compounding Strategies with Nat Jones

    Methylene Blue Topical Formulations and Advanced Dermatology Compounding Strategies with Nat Jones
    Jan 29 2026
    In this episode, discover innovative dermatology compounding formulations featuring methylene blue for anti-aging skincare. Clinical pharmacist Nat Jones discusses PCCA's USP-grade methylene and the need for quality. Methylene blue may play a role in collagen stimulation, hyaluronic acid production, and UV protection. Also, learn about bio-peptide cream bases, research on carbamazepine and plaque psoriasis as well as research on losartan and hypertrophic scars. Explore evidence-based topical treatments that may be appropriate for patients in compounding pharmacies. Perfect for pharmacists seeking advanced dermatological formulation strategies and cosmeceutical applications.

    Learn more by visiting our blog: Methylene Blue: Something Old and Something Blue

    Working with Methylene Blue: Best Practices for Compounding and Cleanup

    Methylene Blue: From Textile Dye to Potential Clinical Wonder
    Show more Show less
    26 mins
  • Industry Leader: APC Blue Print with Tenille Davis and Erin Micheal

    Industry Leader: APC Blue Print with Tenille Davis and Erin Micheal
    Nov 3 2025

    In this episode of a Mortar and Pestle, Tenille Davis, Chief Advocacy Officer for the Alliance for Pharmacy Compounding, joins host Mike De Lisio and guest co-host Erin Michael, Director of Member Engagement, to discuss the APC Blue Print, a blueprint for eliminating redundant, unauthorized, or ineffective regulation that impedes patient access to compounded drugs.
    Show more Show less
    23 mins
No reviews yet